127 related articles for article (PubMed ID: 18646322)
1. P-glycoprotein expression in HTLV-III cells after treatment with HIV-1 protease inhibitors.
Sánchez Mdel C; López P; Vélez R; Yamamura Y
Ethn Dis; 2008; 18(2 Suppl 2):S2-60-4. PubMed ID: 18646322
[TBL] [Abstract][Full Text] [Related]
2. Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells.
Dupuis ML; Flego M; Molinari A; Cianfriglia M
HIV Med; 2003 Oct; 4(4):338-45. PubMed ID: 14525546
[TBL] [Abstract][Full Text] [Related]
3. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
Lucia MB; Rutella S; Leone G; Vella S; Cauda R
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):321-30. PubMed ID: 11468419
[TBL] [Abstract][Full Text] [Related]
4. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
5. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
Washington CB; Duran GE; Man MC; Sikic BI; Blaschke TF
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):203-9. PubMed ID: 9803961
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of P-glycoprotein by HIV protease inhibitors increases intracellular accumulation of berberine in murine and human macrophages.
Zha W; Wang G; Xu W; Liu X; Wang Y; Zha BS; Shi J; Zhao Q; Gerk PM; Studer E; Hylemon PB; Pandak WM; Zhou H
PLoS One; 2013; 8(1):e54349. PubMed ID: 23372711
[TBL] [Abstract][Full Text] [Related]
7. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
[TBL] [Abstract][Full Text] [Related]
8. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
Jones K; Bray PG; Khoo SH; Davey RA; Meaden ER; Ward SA; Back DJ
AIDS; 2001 Jul; 15(11):1353-8. PubMed ID: 11504956
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors.
Richter M; Gyémánt N; Molnár J; Hilgeroth A
Pharm Res; 2004 Oct; 21(10):1862-6. PubMed ID: 15553233
[TBL] [Abstract][Full Text] [Related]
10. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe.
Schmitt C; Kaeser B; Riek M; Bech N; Kreuzer C
Int J Clin Pharmacol Ther; 2010 Mar; 48(3):192-9. PubMed ID: 20197013
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein in blood CD4 cells of HIV-1-infected patients treated with protease inhibitors.
Bossi P; Legrand O; Faussat AM; Legrand M; Bricaire F; Marie JP; Agut H; Diquet B; Katlama C; Huraux JM; Calvez V
HIV Med; 2003 Jan; 4(1):67-71. PubMed ID: 12534962
[TBL] [Abstract][Full Text] [Related]
12. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro.
Chandler B; Almond L; Ford J; Owen A; Hoggard P; Khoo S; Back D
J Acquir Immune Defic Syndr; 2003 Aug; 33(5):551-6. PubMed ID: 12902797
[TBL] [Abstract][Full Text] [Related]
13. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
Gupta A; Zhang Y; Unadkat JD; Mao Q
J Pharmacol Exp Ther; 2004 Jul; 310(1):334-41. PubMed ID: 15007102
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
Valer L; de Mendoza C; Soriano V
J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964
[TBL] [Abstract][Full Text] [Related]
15. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir.
Chaillou S; Durant J; Garraffo R; Georgenthum E; Roptin C; Clevenbergh P; Dunais B; Mondain V; Roger PM; Dellamonica P
HIV Clin Trials; 2002; 3(6):493-501. PubMed ID: 12501133
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J
HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
Shiraki N; Hamada A; Yasuda K; Fujii J; Arimori K; Nakano M
Biol Pharm Bull; 2000 Dec; 23(12):1528-31. PubMed ID: 11145192
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.
Huisman MT; Smit JW; Wiltshire HR; Hoetelmans RM; Beijnen JH; Schinkel AH
Mol Pharmacol; 2001 Apr; 59(4):806-13. PubMed ID: 11259625
[TBL] [Abstract][Full Text] [Related]
19. Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.
Lucia MB; Anu R; Handley M; Gillet JP; Wu CP; De Donatis GM; Cauda R; Gottesman MM
Br J Cancer; 2011 Aug; 105(4):513-22. PubMed ID: 21829205
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 protease inhibitors. A review for clinicians.
Deeks SG; Smith M; Holodniy M; Kahn JO
JAMA; 1997 Jan; 277(2):145-53. PubMed ID: 8990341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
